These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 19365143)

  • 41. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
    Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
    Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fetal plasma leptin concentrations: relationship with different intrauterine growth patterns from 19 weeks to term.
    Cetin I; Morpurgo PS; Radaelli T; Taricco E; Cortelazzi D; Bellotti M; Pardi G; Beck-Peccoz P
    Pediatr Res; 2000 Nov; 48(5):646-51. PubMed ID: 11044486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maternal and fetal cord blood lipids in intrauterine growth restriction.
    Pecks U; Brieger M; Schiessl B; Bauerschlag DO; Piroth D; Bruno B; Fitzner C; Orlikowsky T; Maass N; Rath W
    J Perinat Med; 2012 Jan; 40(3):287-96. PubMed ID: 22505508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrauterine growth restriction is associated with changes in polyunsaturated fatty acid fetal-maternal relationships.
    Cetin I; Giovannini N; Alvino G; Agostoni C; Riva E; Giovannini M; Pardi G
    Pediatr Res; 2002 Nov; 52(5):750-5. PubMed ID: 12409524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maternal and umbilical venous adrenomedullin and nitric oxide levels in intrauterine growth restriction.
    Akturk A; Onal EE; Atalay Y; Yurekli M; Erbas D; Okumus N; Turkyilmaz C; Unal S; Ergenekon E; Koc E; Himmetoglu O
    J Matern Fetal Neonatal Med; 2007 Jul; 20(7):521-5. PubMed ID: 17674265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perinatal changes of circulating N-terminal pro B-type natriuretic peptide (NT-proBNP) in normal and intrauterine-growth-restricted pregnancies.
    Iacovidou N; Briana DD; Boutsikou M; Gourgiotis D; Baka S; Vraila VM; Hassiakos D; Malamitsi-Puchner A
    Hypertens Pregnancy; 2007; 26(4):463-71. PubMed ID: 18066964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
    Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
    J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Beta-2-microglobulin levels in intrauterine growth-restricted and normal pregnancies.
    Kontara L; Briana DD; Baka S; Boutsikou M; Marmarinos A; Gourgiotis D; Malamitsi-Puchner A
    Fetal Diagn Ther; 2008; 24(3):220-4. PubMed ID: 18753761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition.
    Wadsack C; Tabano S; Maier A; Hiden U; Alvino G; Cozzi V; Hüttinger M; Schneider WJ; Lang U; Cetin I; Desoye G
    Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E476-84. PubMed ID: 17003234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potential role of the lectin pathway of complement in the host defence of full-term intrauterine growth restricted neonates at birth.
    Briana DD; Liosi S; Gourgiotis D; Boutsikou M; Baka S; Marmarinos A; Hassiakos D; Malamitsi-Puchner A
    J Matern Fetal Neonatal Med; 2012 May; 25(5):531-4. PubMed ID: 22082351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intrauterine growth restriction and circulating neurotrophin levels at term.
    Malamitsi-Puchner A; Nikolaou KE; Economou E; Boutsikou M; Boutsikou T; Kyriakakou M; Puchner KP; Hassiakos D
    Early Hum Dev; 2007 Jul; 83(7):465-9. PubMed ID: 17071024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
    Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of smoking on concentrations of receptor activator of nuclear factor kappa B ligand and osteoprotegerin in human gingival crevicular fluid.
    Tang TH; Fitzsimmons TR; Bartold PM
    J Clin Periodontol; 2009 Sep; 36(9):713-8. PubMed ID: 19570104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients.
    Buduneli N; Biyikoğlu B; Sherrabeh S; Lappin DF
    J Clin Periodontol; 2008 Oct; 35(10):846-52. PubMed ID: 18727653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.